ANDA 86418, held by G.D. Searle. Metaraminol Bitartrate.
As of Nov 21, 2026, ANDA 86418 (Metaraminol Bitartrate), held by G.D. Searle, was not approved, with 0 approved supplements and 0 published complete response letters.
| Metaraminol BitartrateEQ 10MG BASE/ML · injectable;injection | Metaraminol Bitartrate | Discontinued |
| Metaraminol BitartrateEQ 20MG BASE/ML · injectable;injection | Metaraminol Bitartrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters